Top

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival (PFS) and response rates compared to standard of care for women with certain types of breast and ovarian cancers. These studies were presented today in Barcelona as late-breaking abstracts at the European Society for Medical Oncology Congress 2019. As the data matures, the investigators suggest...

BY Scott Merville

Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...

BY Devon Carter

DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...

September is Ovarian Cancer Awareness Month, an annual time to bring attention to the impact of the disease. This year, more than 22,000 women will be diagnosed with ovarian cancer and roughly 14,000 will die from the disease, according to the American Cancer Society. It ranks fifth in cancer deaths among women and accounts for more deaths than any other gynecologic malignancy.

Despite the emergence of new targeted therapies in...

BY Scott Merville

When Elizabeth White started a new job as executive director of the Michigan Ovarian Cancer Alliance in 2017, she decided it...

BY Ron Gilmore

A study of high-grade ovarian cancer has shown the enzyme protein kinase C iota (PRKCI) to be an ovarian oncogene, suggesting PRKCI inhibition...

BY Laura Sussman

For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...

BY Karen Lu, M.D. and Mark Ebell, M.D.

The majority of women diagnosed with ovarian cancer face a difficult journey of repeated treatments that include aggressive surgeries and...

BY Scott Merville

Approaches to cancer treatment developed by MD Anderson researchers as part of the institution’s Moon Shots Program will be, in part, the...